Onxeo is a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Co.'s orphan oncology product portfolio comprises 3 products (Livatag®, Beleodaq®, and AsiDNA™), ranging from preclinical to advanced phases of clinical development.
  • TickerONXEO
  • ISINFR0010095596
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

1 director bought

A director at Onxeo bought 300,000 shares at 1.199EUR and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board member...

Dr Jonas Peciulis

Onxeo - Phase I with AsiDNA iv starts; first data in H218

On 24 April, Onxeo announced that the first patient had been treated with AsiDNA, a first-in-class DNA break repair inhibitor, via systemic administration in the Phase I trial. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection. Alongside the Phase I trial Onxeo is conducting a broad preclinical programme that explores AsiDNA in various settings and combinations with other drugs. Two abstracts with preclinical data were presented at the American Association for Cancer Research conference in April potentially demonstrating unique characte...

Dr Jonas Peciulis

Onxeo - Introducing platON; AsiDNA approaches Phase I

Onxeo has experienced a volatile 2017 mainly due to Livatag’s Phase III ReLive not meeting its primary endpoint. The out-licensing of Validive, fresh data from several preclinical studies with core assets – AsiDNA and belinostat combinations – were more positive recent developments. Although the share price halved after the disappointing ReLive data, the asset portfolio has been radically reshaped to focus on DNA break repair inhibition and epigenetics and Onxeo has cash reach until 2020. Our updated valuation is €218m (vs €350m) or €4.3/share.

Dr Jonas Peciulis

Onxeo - Livatag's future less clear; Validive finds partner

As announced on Monday evening, the Phase III stage Livatag did not meet the primary endpoint of improving survival in hepatocellular carcinoma (HCC) patients after treatment failure with sorafenib over the comparison arm, where patients received the standard of care (SoC). This morning, Onxeo announced that it had out-licensed its Phase III ready orphan oncology asset Validive to Monopar Therapeutics for a total deal value of $108m and up to double-digit royalties.

Dr Jonas Peciulis

First significant milestone with AsiDNA achieved

Yesterday Onxeo announced its first preclinical proof-of-concept data with AsiDNA demonstrating the potential to be administrated intravenously. AsiDNA, a first-in-class DNA repair inhibitor, has already been tested in a Phase I trial with melanoma patients and showed promising results in terms of safety and initial signs of efficacy administered via local injection. After Onxeo acquired the drug in February 2016, the company repositioned the development and now seeking to establish a pre-clinical dossier to start human trials with intravenous injection, which would vastly increase the address...

Dr Jonas Peciulis

Multiple events in 2017

The major near-term catalyst for Onxeo will likely be the Livatag Phase III data in second-line liver cancer, which is expected around mid-2017. During 2017 we also expect new asset AsiDNA to advance into clinical testing, and progress with Beleodaq (belinostat), which could start the regulatory required Phase III trial. Onxeo is increasingly focused on exploring further opportunities for these assets, and has a number of preclinical collaborations ongoing. While data from these early-stage studies are not likely to be a major share price driver, in the longer term, these efforts could help to...

1 director bought

A director at Onxeo bought 300,000 shares at 1.199EUR and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board member...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 16/05/2018

Si les rémunérations 2017 de Mme Gréciet, Directrice Générale, présentent des montants plutôt acceptables, le réel problème de sa rémunération demeure que sa rémunération sous forme d'options et d'actions de performance est assortie de conditions de performance court-termistes. Non seulement cela ne répond pas aux préconisations de Proxinvest et des investisseurs, mais cela demeure plutôt étonnant de la part d'une biotech. En effet, ces sociétés biopharmaceutiques ont un business-model qui repose lui-même sur le très long-terme ; il semblerait donc tout à fait cohérent que les rémunérations l...

Jehanne Leroy

Etude de l'AG du 26/04/2017

La société se référant au code MiddleNext, les actionnaires ont, en vertu de la Loi Sapin 2, pour la première fois l'occasion de se prononcer sur les rémunérations des dirigeants.Si les rémunérations de Mme Gréciet, Directrice Générale, présentent des montants plutôt acceptables, le réel problème de sa rémunération demeure que sa rémunération sous forme d'options et d'actions de performance est assortie de conditions de performance court-termiste.Non seulement cela ne répond pas aux préconisations de Proxinvest et des investisseurs, mais cela demeure plutôt étonnant de la part d'une biotech. E...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch